|Bid||168.34 x 1000|
|Ask||168.90 x 800|
|Day's range||158.65 - 170.20|
|52-week range||121.32 - 464.00|
|Beta (5Y monthly)||-0.28|
|PE ratio (TTM)||3.22|
|Earnings date||08 Aug 2022|
|Forward dividend & yield||2.11 (1.32%)|
|Ex-dividend date||02 June 2022|
|1y target est||259.76|
An overall market rebound and Tuesday's authorization of boosters for kids likely propelled the stock higher.
Moderna (MRNA) stock rises more than 4% on May 17. The COVID-19 vaccine-maker attracts investors on the back of a promising update from one of its competitors.
Pfizer (PFE) and partner BioNTech gets authorization for emergency use of booster dose of its COVID-19 vaccine, Comirnaty, in children aged between 5 years and 11 years.